Genetics of leprosy reactions: An overview

Memorias do Instituto Oswaldo Cruz

Volumn 107, Issue SUPPL.1, 2012, Pages 132-142

  Fava, Vinicius ^a,b,c   Orlova, Marianna ^a,b   Cobat, Aurélie ^a,b   Alcaïs, Alexandre ^d,e,f   Mira, Marcelo ^c   Schurr, Erwin ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c PONTIFICAL CATHOLIC UNIVERSITY OF PARANÁ   (Brazil)

^d IMAGINE INSTITUTE   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Erythema nodosum leprosum; Host genetic background; Leprosy; Reversal reactionU; Type 1 leprosy reaction; Type 2 leprosy reaction

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; GENETICS; HUMAN; IMMUNOLOGY; LEPROSY; PATHOLOGY;

BIOLOGICAL MARKERS; HUMANS; LEPROSY;

EID: 84871494087     PISSN: 00740276     EISSN: 16788060     Source Type: Journal    
DOI: 10.1590/S0074-02762012000900020     Document Type: Article

References (141)

1. Abel L, Sanchez FO, Oberti J, Thuc NV, Hoa LV, Lap VD, Skamene E, Lagrange PH, Schurr E 1998. Susceptibility to leprosy is linked to the human NRAMP1 gene. J Infect Dis 177: 133-145.
2. Akira S, Takeda K 2004. Toll-like receptor signalling. Nat Rev Immunol 4: 499-511.
3. Alcais A, Alter A, Antoni G, Orlova M, Van Thuc N, Singh M, Vanderborght PR, Katoch K, Mira MT, Thai VH, Huong NT, Ba NN, Moraes M, Mehra N, Schurr E, Abel L 2007. Stepwise replication identifies a low-producing lymphotoxin-[alpha] allele as a major risk factor for early-onset leprosy. Nat Genet 39: 517-522.
4. Alcais A, Mira M, Casanova JL, Schurr E, Abel L 2005. Genetic dissection of immunity in leprosy. Curr Opin Immunol 17: 44-48.
5. Alcais A, Sanchez FAO, Thuc NAV, Lap VAD, Oberti J, Lagrange PAH, Schurr E, Abel L 2000. Granulomatous reaction to intradermal injection of lepromin (Mitsuda reaction) is linked to the human NRAMP1 gene in Vietnamese leprosy sibships. J Infect Dis 181: 302-308.
6. Alter A, de Leseleuc L, Van Thuc N, Thai VH, Huong NT, Ba NN, Cardoso CC, Grant AV, Abel L, Moraes MO, Alcais A, Schurr E 2010. Genetic and functional analysis of common MRC1 exon 7 polymorphisms in leprosy susceptibility. Hum Genet 127: 337-348.
7. Andersson AK, Atkinson SE, Khanolkar-Young S, Chaduvula M, Jain S, Suneetha L, Suneetha S, Lockwood DN 2007. Alteration of the cortisol-cortisone shuttle in leprosy type 1 reactions in leprosy patients in Hyderabad, India. Immunol Lett 109: 72-75.
8. Barnes PF, Chatterjee D, Brennan PJ, Rea TH, Modlin RL 1992. Tumor necrosis factor production in patients with leprosy. Infect Immun 60: 1441-1446.
9. Becx-Bleumink M, Berhe D 1992. Occurrence of reactions, their diagnosis and management in leprosy patients treated with multidrug therapy; experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia. Int J Lepr Other Mycobact Dis 60: 173-184.
10. Behr MA, Schurr E 2006. Mycobacteria in Crohn's disease: a persistent hypothesis. Inflamm Bowel Dis 12: 1000-1004.
11. Belgaumkar VA, Gokhale NR, Mahajan PM, Bharadwaj R, Pandit DP, Deshpande S 2007. Circulating cytokine profiles in leprosy patients. Lepr Rev 78: 223-230.
12. Benard G, Sakai-Valente NY, Bianconcini Trindade MA 2009. Concomitant Lucio phenomenon and erythema nodosum in a leprosy patient: clues for their distinct pathogeneses. Am J Dermatopathol 31: 288-292.
13. Berrington WR, Macdonald M, Khadge S, Sapkota BR, Janer M, Hagge DA, Kaplan G, Hawn TR 2010. Common polymorphisms in the NOD2 gene region are associated with leprosy and its reactive states. J Infect Dis 201: 1422-1435.
14. Bochud PY, Hawn Thomas ÂR, Siddiqui MÂR, Saunderson P, Britton S, Abraham I, Argaw Azeb  T, Janer M, Zhao Lue ÂP, Kaplan G, Aderem A 2008. Toll-like receptor 2 (TLR2) polymorphisms are associated with reversal reaction in leprosy. J Infect Dis 197: 253-261.
15. Britton WJ, Lockwood DN 2004. Leprosy. Lancet 363: 1209-1219.
16. Callegaro-Filho D, Shrestha N, Burdick AE, Haslett PA 2010. A potential role for complement in immune evasion by Mycobacterium leprae. J Drugs Dermatol 9: 1373-1382.
17. Canonne-Hergaux F, Calafat J, Richer E, Cellier M, Grinstein S, Borregaard N, Gros P 2002. Expression and subcellular localization of NRAMP1 in human neutrophil granules. Blood 100: 268-275.
18. Carroll MC 1998. The role of complement and complement receptors in induction and regulation of immunity. Annu Rev Immunol 16: 545-568.
19. Castellucci L, Menezes E, Oliveira J, Magalhaes A, Guimaraes LH, Lessa M, Ribeiro S, Reale J, Noronha EF, Wilson ME, Duggal P, Beaty TH, Jeronimo S, Jamieson SE, Bales A, Blackwell JM, de Jesus AR, Carvalho EM 2006. IL-6-174 G/C promoter polymorphism influences susceptibility to mucosal, but not localized cutaneous leishmaniasis in Brazil. J Infect Dis 194: 519-527.
20. de Messias IJ, Santamaria J, Brenden M, Reis A, Mauff G 1993. Association of C4B deficiency (C4B*Q0) with erythema nodosum in leprosy. Clin Exp Immunol 92: 284-287.
21. Donner RS, Shively JA 1967. The "Lucio phenomenon" in diffuse leprosy. Ann Intern Med 67: 831-836.
22. Faber WR, Jensema AJ, Goldschmidt WF 2006. Treatment of recurrent erythema nodosum leprosum with infliximab. N Engl J Med 355: 739.
23. Feuth M, Brandsma JW, Faber WR, Bhattarai B, Feuth T, Anderson AM 2008. Erythema nodosum leprosum in Nepal: a retrospective study of clinical features and response to treatment with prednisolone or thalidomide. Lepr Rev 79: 254-269.
24. Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, Woo P 1998. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 102: 1369-1376.
25. Foss NT, de Oliveira EB, Silva CL 1993. Correlation between TNF production, increase of plasma C-reactive protein level and suppression of T lymphocyte response to concanavalin A during erythema nodosum leprosum. Int J Lepr Other Mycobact Dis 61: 218-226.
26. Franchi L, Warner N, Viani K, Nunez G 2009. Function of Nod-like receptors in microbial recognition and host defense. Immunol Rev 227: 106-128.
27. Fritz JH, Girardin SE, Fitting C, Werts C, Mengin-Lecreulx D, Caroff M, Cavaillon JM, Philpott DJ, Adib-Conquy M 2005. Synergistic stimulation of human monocytes and dendritic cells by Toll-like receptor 4 and NOD1 and NOD2-activating agonists. Eur J Immunol 35: 2459-2470.
28. Fuhlbrigge RC, Kieffer JD, Armerding D, Kupper TS 1997. Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells. Nature 389: 978-981.
29. Gay NJ, Gangloff M 2007. Structure and function of Toll receptors and their ligands. Annu Rev Biochem 76: 141-165.
30. Govoni G, Gros P 1998. Macrophage NRAMP1 and its role in resistance to microbial infections. Inflamm Res 47: 277-284.
31. Greenwood CM, Fujiwara TM, Boothroyd LJ, Miller MA, Frappier D, Fanning EA, Schurr E, Morgan K 2000. Linkage of tuberculosis to chromosome 2q35 loci including NRAMP1 in a large aboriginal Canadian family. Am J Hum Genet 67: 405-416.
32. Guerreiro CS, Ferreira P, Tavares L, Santos PM, Neves M, Brito M, Cravo M 2009. Fatty acids, IL-6 and TNF-alpha polymorphisms: an example of nutrigenetics in Crohn's disease. Am J Gastroenterol 104: 2241-2249.
33. Han XY, Seo Y-H, Sizer KC, Schoberle T, May GS, Spencer JS, Li W, Nair RG 2008. A new Mycobacterium species causing diffuse lepromatous leprosy. Am J Clin Pathol 130: 856-864.
34. Han XY, Sizer KC, Thompson EJ, Kabanja J, Li J, Hu P, Gomez-Valero L, Silva FJ 2009. Comparative sequence analysis of Mycobacterium leprae and the new leprosy-causing Mycobacterium lepromatosis. J Bacteriol 191: 6067-6074.
35. Hawn TR, Misch EA, Dunstan SJ, Thwaites GE, Lan NT, Quy HT, Chau TT, Rodrigues S, Nachman A, Janer M, Hien TT, Farrar JJ, Aderem A 2007. A common human TLR1 polymorphism regulates the innate immune response to lipopeptides. Eur J Immunol 37: 2280-2289.
36. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, Almer S, Tysk C, O'Morain CA, Gassull M, Binder V, Finkel Y, Cortot A, Modigliani R, Laurent-Puig P, Gower-Rousseau C, Macry J, Colombel JF, Sahbatou M, Thomas G 2001. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411: 599-603.
37. Hussain R, Lucas SB, Kifayet A, Jamil S, Raynes J, Uqaili Z, Dockrell HM, Chiang TJ, McAdam KP 1995. Clinical and histological discrepancies in diagnosis of ENL reactions classified by assessment of acute phase proteins SAA and CRP. Int J Lepr Other Mycobact Dis 63: 222-230.
38. Jessamine PG, Desjardins M, Gillis T, Scollard D, Jamieson F, Broukhanski G, Chedore P, McCarthy A 2012. Leprosy-like illness in a patient with Mycobacterium lepromatosis from Ontario, Canada. J Drugs Dermatol 11: 229-233.
39. Johnson CM, Lyle EA, Omueti KO, Stepensky VA, Yegin O, Alpsoy E, Hamann L, Schumann RR, Tapping RI 2007. Cutting edge: a common polymorphism impairs cell surface trafficking and functional responses of TLR1, but protects against leprosy. J Immunol 178: 7520-7524.
40. Kahawita IP, Lockwood DN 2008. Towards understanding the pathology of erythema nodosum leprosum. Trans R Soc Trop Med Hyg 102: 329-337.
41. Kahawita IP, Walker SL, Lockwood DNJ 2008. Leprosy type 1 reactions and erythema nodosum leprosum. An bras Dermatol 83: 75-82.
42. Kojima Y, Kinouchi Y, Takahashi S, Negoro K, Hiwatashi N, Shimosegawa T 2001. Inflammatory bowel disease is associated with a novel promoter polymorphism of natural resistance-associated macrophage protein 1 (NRAMP1) gene. Tissue Antigens 58: 379-384.
43. Krutzik SR, Ochoa MT, Sieling PA, Uematsu S, Ng YW, Legaspi A, Liu PT, Cole ST, Godowski PJ, Maeda Y, Sarno EN, Norgard MV, Brennan PJ, Akira S, Rea TH, Modlin RL 2003. Activation and regulation of Toll-like receptors 2 and 1 in human leprosy. Nat Med 9: 525-532.
44. Krutzik SR, Tan B, Li H, Ochoa MT, Liu PT, Sharfstein SE, Graeber TG, Sieling PA, Liu YJ, Rea TH, Bloom BR, Modlin RL 2005. TLR activation triggers the rapid differentiation of monocytes into macrophages and dendritic cells. Nat Med 11: 653-660.
45. Kumar B, Dogra S, Kaur I 2004. Epidemiological characteristics of leprosy reactions: 15 years experience from North India. Int J Lepr Other Mycobact Dis 72: 125-133.
46. Latapi F, Chavez-Zamora A 1948. The"spotted" leprosy of Lucio: an introduction to its clinical and histological study. Int J Lepr 16: 421-437.
47. Leoratti FM, Farias L, Alves FP, Suarez-Mutis MC, Coura JR, Kalil J, Camargo EP, Moraes SL, Ramasawmy R 2008. Variants in the Toll-like receptor signaling pathway and clinical outcomes of malaria. J Infect Dis 198: 772-780.
48. Li X, Yang Y, Zhou F, Zhang Y, Lu H, Jin Q, Gao L 2011. SLC11A1 (NRAMP1) polymorphisms and tuberculosis susceptibility: updated systematic review and meta-analysis. PLoS ONE 6: e15831.
49. Little D, Khanolkar-Young S, Coulthart A, Suneetha S, Lockwood DN 2001. Immunohistochemical analysis of cellular infiltrate and gamma interferon, interleukin-12 and inducible nitric oxide synthase expression in leprosy type 1 (reversal) reactions before and during prednisolone treatment. Infect Immun 69: 3413-3417.
50. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, Ochoa MT, Schauber J, Wu K, Meinken C, Kamen DL, Wagner M, Bals R, Steinmeyer A, Zugel U, Gallo RL, Eisenberg D, Hewison M, Hollis BW, Adams JS, Bloom BR, Modlin RL 2006. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311: 1770-1773.
51. Lockwood DN, Sinha HH 1999. Pregnancy and leprosy: a comprehensive literature review. Int J Lepr Other Mycobact Dis 67: 6-12.
52. Lockwood DN, Suneetha L, Sagili KD, Chaduvula MV, Mohammed I, van Brakel W, Smith WC, Nicholls P, Suneetha S 2011. Cytokine and protein markers of leprosy reactions in skin and nerves: baseline results for the North Indian INFIR cohort. PLoS Negl Trop Dis 5: e1327.
53. Lucio R, Alvarado Y 1852. Opusculo sobre el mal de San Lazaro o elefanciasis de los Griegos, M Murguia y Cia, Mexico, 53 pp.
54. Mabalay MC, Helwig EB, Tolentino JG, Binford CH 1965. The histopathology and histochemistry of erythema nodosum leprosum. Int J Lepr 33: 28-49.
55. Malik S, Abel L, Tooker H, Poon A, Simkin L, Girard M, Adams GJ, Starke JR, Smith KC, Graviss EA, Musser JM, Schurr E 2005. Alleles of the NRAMP1 gene are risk factors for pediatric tuberculosis disease. Proc Natl Acad Sci USA 102: 12183-12188.
56. Manandhar R, Le Master JW, Roche PW 1999. Risk factors for erythema nodosum leprosum. Int J Lepr Other Mycobact Dis 67: 270-278.
57. Marquet S, Sanchez FO, Arias M, Rodriguez J, Paris SC, Skamene E, Schurr E, Garcia LF 1999. Variants of the human NRAMP1 gene and altered human immunodeficiency virus infection susceptibility. J Infect Dis 180: 1521-1525.
58. Mattos KA, Oliveira VG, D'Avila H, Rodrigues LS, Pinheiro RO, Sarno EN, Pessolani MC, Bozza PT 2011. TLR6-driven lipid droplets in Mycobacterium leprae-infected Schwann cells: immunoinflammatory platforms associated with bacterial persistence. J Immunol 187: 2548-2558.
59. Meisner SJ, Mucklow S, Warner G, Sow SO, Lienhardt C, Hill AV 2001. Association of NRAMP1 polymorphism with leprosy type, but not susceptibility to leprosy per se in west Africans. Am J Trop Med Hyg 65: 733-735.
60. Mira MT 2006. Genetic host resistance and susceptibility to leprosy. Microbies Infection 8: 1124-1131.
61. Mira MT, Alcais A, Nguyen VT, Moraes MO, Di Flumeri C, Vu HT, Mai CP, Nguyen TH, Nguyen NB, Pham XK, Sarno EN, Alter A, Montpetit A, Moraes ME, Moraes JR, Dore C, Gallant CJ, Lepage P, Verner A, Van de Vosse E, Hudson TJ, Abel L, Schurr E 2004. Susceptibility to leprosy is associated with PARK2 and PACRG. Nature 427: 636-640.
62. Mira MT, Alcais A, Van Thuc N, Thai VH, Huong NT, Ba NN, Verner A, Hudson TJ, Abel L, Schurr E 2003. Chromosome 6q25 is linked to susceptibility to leprosy in a Vietnamese population. Nat Genet 33: 412-415.
63. Misch EA, Macdonald M, Ranjit C, Sapkota BR, Wells RD, Siddiqui MR, Kaplan G, Hawn TR 2008. Human TLR1 deficiency is associated with impaired mycobacterial signaling and protection from leprosy reversal reaction. PLoS Negl Trop Dis 2: e231.
64. Modlin RL, Bakke AC, Vaccaro SA, Horwitz DA, Taylor CR, Rea TH 1985. Tissue and blood T-lymphocyte subpopulations in erythema nodosum leprosum. Arch Dermatol 121: 216-219.
65. Modlin RL, Gebhard JF, Taylor CR, Rea TH 1983. In situ characterization of T lymphocyte subsets in the reactional states of leprosy. Clin Exp Immunol 53: 17-24.
66. Modlin RL, Hofman FM, Horwitz DA, Husmann LA, Gillis S, Taylor CR, Rea TH 1984. In situ identification of cells in human leprosy granulomas with monoclonal antibodies to interleukin 2 and its receptor. J Immunol 132: 3085-3090.
67. Mohamed HS, Ibrahim ME, Miller EN, White JK, Cordell HJ, Howson JM, Peacock CS, Khalil EA, El Hassan AM, Blackwell JM 2004. SLC11A1 (formerly NRAMP1) and susceptibility to visceral leishmaniasis in The Sudan. Eur J Hum Genet 12: 66-74.
68. Moraes MO, Sampaio EP, Nery JA, Saraiva BC, Alvarenga FB, Sarno EN 2001. Sequential erythema nodosum leprosum and reversal reaction with similar lesional cytokine mRNA patterns in a borderline leprosy patient. Br J Dermatol 144: 175-181.
69. Moraes MO, Sarno EN, Almeida AS, Saraiva BC, Nery JA, Martins RC, Sampaio EP 1999. Cytokine mRNA expression in leprosy: a possible role for interferon-gamma and interleukin-12 in reactions (RR and ENL). Scand J Immunol 50: 541-549.
70. Moraes MO, Sarno EN, Teles RM, Almeida AS, Saraiva BC, Nery JA, Sampaio EP 2000. Anti-inflammatory drugs block cytokine mRNA accumulation in the skin and improve the clinical condition of reactional leprosy patients. J Invest Dermatol 115: 935-941.
71. Naafs B 2000. Viewpoint: leprosy after the year 2000. Trop Med Int Health 5: 400-403.
72. Naafs B 2006. Treatment of leprosy: science or politics? Trop Med Int Health 11: 268-278.
73. Nestle FO, Kaplan DH, Barker J 2009. Psoriasis. N Engl J Med 361: 496-509.
74. Nibali L, D'Aiuto F, Donos N, Griffiths GS, Parkar M, Tonetti MS, Humphries SE, Brett PM 2009. Association between periodontitis and common variants in the promoter of the interleukin-6 gene. Cytokine 45: 50-54.
75. Noguchi E, Homma Y, Kang X, Netea MG, Ma X 2009. A Crohn's disease-associated NOD2 mutation suppresses transcription of human IL-10 by inhibiting activity of the nuclear ribonucleoprotein hnRNP-A1. Nat Immunol 10: 471-479.
76. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, Britton H, Moran T, Karaliuskas R, Duerr RH, Achkar JP, Brant SR, Bayless TM, Kirschner BS, Hanauer SB, Nunez G, Cho JH 2001. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411: 603-606.
77. Oliveira RB, Moraes MO, Oliveira EB, Sarno EN, Nery JA, Sampaio EP 1999. Neutrophils isolated from leprosy patients release TNF-alpha and exhibit accelerated apoptosis in vitro. J Leukoc Biol 65: 364-371.
78. Oliveira RB, Ochoa MT, Sieling PA, Rea TH, Rambukkana A, Sarno EN, Modlin RL 2003. Expression of Toll-like receptor 2 on human Schwann cells: a mechanism of nerve damage in leprosy. Infect Immun 71: 1427-1433.
79. Omueti KO, Mazur DJ, Thompson KS, Lyle EA, Tapping RI 2007. The polymorphism P315L of human Toll-like receptor 1 impairs innate immune sensing of microbial cell wall components. J Immunol 178: 6387-6394.
80. Orlova M, Di Pietrantonio T, Schurr E 2011. Genetics of infectious diseases: hidden etiologies and common pathways. Clin Chem Lab Med 49: 1427-1437.
81. Pannikar V 2009. Enhanced global strategy for further reducing the disease burden due to leprosy: 2011-2015. Lepr Rev 80: 353-354.
82. Pascual M, Nieto A, Mataran L, Balsa A, Pascual-Salcedo D, Martin J 2000. IL-6 promoter polymorphisms in rheumatoid arthritis. Genes Immun 1: 338-340.
83. Pedroza LS, Sauma MF, Vasconcelos JM, Takeshita LY, Ribeiro-Rodrigues EM, Sastre D, Barbosa CM, Chies JA, Veit TD, Lima CP, Oliveira LF, Henderson BL, Castro AP, Maia MH, Barbosa FB, Santos SE, Guerreiro JF, Sena L, Santos EJ 2011. Systemic lupus erythematosus: association with KIR and SLC11A1 polymorphisms, ethnic predisposition and influence in clinical manifestations at onset revealed by ancestry genetic markers in an urban Brazilian population. Lupus 20: 265-273.
84. Pocaterra L, Jain S, Reddy R, Muzaffarullah S, Torres O, Suneetha S, Lockwood DN 2006. Clinical course of erythema nodosum leprosum: an 11-year cohort study in Hyderabad, India. Am J Trop Med Hyg 74: 868-879.
85. Poikonen K, Lajunen T, Silvennoinen-Kassinen S, Leinonen M, Saikku P 2009. Effects of CD14, TLR2, TLR4, LPB and IL-6 gene polymorphisms on Chlamydia pneumoniae growth in human macrophages in vitro. Scand J Immunol 70: 34-39.
86. Ramien ML, Wong A, Keystone JS 2011. Severe refractory erythema nodosum leprosum successfully treated with the tumor necrosis factor inhibitor etanercept. Clin Infect Dis 52: e133-135.
87. Randhawa AK, Shey MS, Keyser A, Peixoto B, Wells RD, de Kock M, Lerumo L, Hughes J, Hussey G, Hawkridge A, Kaplan G, Hanekom WA, Hawn TR 2011. Association of human TLR1 and TLR6 deficiency with altered immune responses to BCG vaccination in South African infants. PLoS Pathog 7: e1002174.
88. Ranque B, Alcais A, Thuc NV, Woynard S, Thai VH, Huong NT, Ba NN, Khoa PX, Schurr E, Abel L 2005. A recessive major gene controls the mitsuda reaction in a region endemic for leprosy. J Infect Dis 192: 1475-1482.
89. Ranque B, Nguyen Van  T, Vu Hong T, Nguyen Thu H, Nguyen Ngoc B, Pham Xuan  K, Schurr E, Abel L, Alca à SA 2007. Age is an important risk factor for onset and sequelae of reversal reactions in Vietnamese patients with leprosy. Clin Infect Dis 44: 33-40.
90. Ray A, LaForge KS, Sehgal PB 1990. On the mechanism for efficient repression of the interleukin-6 promoter by glucocorticoids: enhancer, TATA box and RNA start site (Inr motif) occlusion. Mol Cell Biol 10: 5736-5746.
91. Rea TH, Sieling PA 1998. Delayed-type hypersensitivity reactions followed by erythema nodosum leprosum. Int J Lepr Other Mycobact Dis 66: 316-327.
92. Ridley DS, Jopling WH 1966. Classification of leprosy according to immunity. A five-group system. Int J Lepr Other Mycobact Dis 34: 255-273.
93. Ridley DS, Radia KB 1981. The histological course of reactions in borderline leprosy and their outcome. Int J Lepr Other Mycobact Dis 49: 383-392.
94. Roach JC, Glusman G, Rowen L, Kaur A, Purcell MK, Smith KD, Hood LE, Aderem A 2005. The evolution of vertebrate Toll-like receptors. Proc Natl Acad Sci USA 102: 9577-9582.
95. Roche M, Convit J, Medina JA, Blomenfeld E 1951. The effects of adrenocorticotropic hormone (ACTH) in lepromatous lepra reaction. Int J Lepr 19: 137-145.
96. Roche PW, Theuvenet WJ, Britton WJ 1991. Risk factors for type-1 reactions in borderline leprosy patients. Lancet 338: 654-657.
97. Rodrigues LS, Hacker MA, Illarramendi X, Castelar Pinheiro MF, da Costa Nery JA, Sarno EN, Vidal Pessolani MC 2011. Circulating levels of insulin-like growth factor-I (IGF-I) correlate with disease status in leprosy. BMC Infect Dis 11: 339.
98. Rook GA, Baker R 1999. Cortisol metabolism, cortisol sensitivity and the pathogenesis of leprosy reactions. Trop Med Int Health 4: 493-498.
99. Rose P, Waters MF 1991. Reversal reactions in leprosy and their management. Lepr Rev 62: 113-121.
100. Sampaio EP, Moraes MO, Nery JA, Santos AR, Matos HC, Sarno EN 1998. Pentoxifylline decreases in vivo and in vitro tumour necrosis factor-alpha (TNF-alpha) production in lepromatous leprosy patients with erythema nodosum leprosum (ENL). Clin Exp Immunol 111: 300-308.
101. San Luciano M, Ozelius L, Lipton RB, Raymond D, Bressman SB, Saunders-Pullman R 2012. Gender differences in the IL-6 -174G>C and ESR2 1730G>A polymorphisms and the risk of Parkinson's disease. Neurosci Lett 506: 312-316.
102. Sapkota BR, Macdonald M, Berrington WR, Misch EA, Ranjit C, Siddiqui MR, Kaplan G, Hawn TR 2010. Association of TNF, MBL and VDR polymorphisms with leprosy phenotypes. Hum Immunol 71: 992-998.
103. Sarno EN, Grau GE, Vieira LM, Nery JA 1991. Serum levels of tumour necrosis factor-alpha and interleukin-1 beta during leprosy reactional states. Clin Exp Immunol 84: 103-108.
104. Saunderson P, Gebre S, Byass P 2000a. ENL reactions in the multibacillary cases of the AMFES cohort in central Ethiopia: incidence and risk factors. Lepr Rev 71: 318-324.
105. Saunderson P, Gebre S, Byass P 2000b. Reversal reactions in the skin lesions of AMFES patients: incidence and risk factors. Lepr Rev 71: 309-317.
106. Sawczenko A, Azooz O, Paraszczuk J, Idestrom M, Croft NM, Savage MO, Ballinger AB, Sanderson IR 2005. Intestinal inflammation-induced growth retardation acts through IL-6 in rats and depends on the -174 IL-6 G/C polymorphism in children. Proc Natl Acad Sci USA 102: 13260-13265.
107. Schaff UY, Shih HH, Lorenz M, Sako D, Kriz R, Milarski K, Bates B, Tchernychev B, Shaw GD, Simon SI 2008. SLIC-1/sorting nexin 20: a novel sorting nexin that directs subcellular distribution of PSGL-1. Eur J Immunol 38: 550-564.
108. Schuring RP, Hamann L, Faber WR, Pahan D, Richardus JH, Schumann RR, Oskam L 2009. Polymorphism N248S in the human Toll-like receptor 1 gene is related to leprosy and leprosy reactions. J Infect Dis 199: 1816-1819.
109. Schurr E, Gros P 2009. A common genetic fingerprint in leprosy and Crohn's disease? N Engl J Med 361: 2666-2668.
110. Scollard DM, Adams LB, Gillis TP, Krahenbuhl JL, Truman RW, Williams DL 2006. The continuing challenges of leprosy. Clin Microbiol Rev 19: 338-381.
111. Scollard DM, Chaduvula MV, Martinez A, Fowlkes N, Nath I, Stryjewska BM, Kearney MT, Williams DL 2011. Increased CXCL10 levels and gene expression in type 1 leprosy reactions. Clin Vaccine Immunol 18: 947-953.
112. Scollard DM, Smith T, Bhoopat L, Theetranont C, Rangdaeng S, Morens DM 1994. Epidemiologic characteristics of leprosy reactions. Int J Lepr Other Mycobact Dis 62: 559-567.
113. Sehgal VN 2005. Lucio's phenomenon/erythema necroticans. Int J Dermatol 44: 602-605.
114. Shannon EJ, Sandoval FG, Morales MJ 2011. In vitro thalidomide does not interfere with the activation of complement by M. leprae. J Drugs Dermatol 10: 274-278.
115. Sousa AL, Fava VM, Sampaio LH, Martelli CM, Costa MB, Mira MT, Stefani MM 2012. Genetic and immunological evidence implicates interleukin 6 as a susceptibility gene for leprosy type 2 reaction. J Infect Dis 205: 1417-1424.
116. Sousa AL, Stefani MM, Pereira GA, Costa MB, Rebello PF, Gomes MK, Narahashi K, Gillis TP, Krahenbuhl JL, Martelli CM 2007. Mycobacterium leprae DNA associated with type 1 reactions in single lesion paucibacillary leprosy treated with single dose rifampin, ofloxacin and minocycline. Am J Trop Med Hyg 77: 829-833.
117. Sreenivasan P, Misra RS, Wilfred D, Nath I 1998. Lepromatous leprosy patients show T helper 1-like cytokine profile with differential expression of interleukin-10 during type 1 and 2 reactions. Immunology 95: 529-536.
118. Stefani MM, Guerra JG, Sousa AL, Costa MB, Oliveira ML, Martelli CT, Scollard DM 2009. Potential plasma markers of type 1 and type 2 leprosy reactions: a preliminary report. BMC Infect Dis 9: 75.
119. Stewart LC, Day AS, Pearson J, Barclay ML, Gearry RB, Roberts RL, Bentley RW 2010. SLC11A1 polymorphisms in inflammatory bowel disease and Mycobacterium avium subspecies paratuberculosis status. World J Gastroenterol 16: 5727-5731.
120. Tada H, Aiba S, Shibata K, Ohteki T, Takada H 2005. Synergistic effect of Nod1 and Nod2 agonists with Toll-like receptor agonists on human dendritic cells to generate interleukin-12 and T helper type 1 cells. Infect Immun 73: 7967-7976.
121. Tadesse A, Abebe M, Bizuneh E, Mulugeta W, Aseffa A, Shannon EJ 2006. Effect of thalidomide on the expression of TNF-alpha m-RNA and synthesis of TNF-alpha in cells from leprosy patients with reversal reaction. Immunopharmacol Immunotoxicol 28: 431-441.
122. Takeda Y, Kaneda K, Jimma F, Shiobara N, Hidaka M, Saniabadi AR, Wakabayashi I 2012. Inhibition of CXCL10 release by monomeric C3bi and C4b. Clin Exp Immunol 167: 149-157.
123. Teixeira MA, Silva NL, Ramos Ade L, Hatagima A, Magalhaes V 2010. NRAMP1 gene polymorphisms in individuals with leprosy reactions attended at two reference centers in Recife, northeastern Brazil. Rev Soc Bras Med Trop 43: 281-286.
124. Trevilatto PC, Scarel-Caminaga RM, de Brito Jr RB, de Souza AP, Line SR 2003. Polymorphism at position -174 of IL-6 gene is associated with susceptibility to chronic periodontitis in a Caucasian Brazilian population. J Clin Periodontol 30: 438-442.
125. van Brakel WH, Khawas IB 1996. Nerve function impairment in leprosy: an epidemiological and clinical study - Part 2. Results of steroid treatment. Lepr Rev 67: 104-118.
126. van Brakel WH, Nicholls PG, Das L, Barkataki P, Suneetha SK, Jadhav RS, Maddali P, Lockwood DN, Wilder-Smith E, Desikan KV 2005. The INFIR Cohort Study: investigating prediction, detection and pathogenesis of neuropathy and reactions in leprosy. Methods and baseline results of a cohort of multibacillary leprosy patients in north India. Lepr Rev 76: 14-34.
127. Vera-Cabrera L, Escalante-Fuentes WG, Gomez-Flores M, Ocampo-Candiani J, Busso P, Singh P, Cole ST 2011. Case of diffuse lepromatous leprosy associated with Mycobacterium lepromatosis. J Clin Microbiol 49: 4366-4368.
128. Verway M, Behr MA, White JH 2010. Vitamin D, NOD2, autophagy and Crohn's disease. Expert Rev Clin Immunol 6: 505-508.
129. Vidal S, Gros P, Skamene E 1995. Natural resistance to infection with intracellular parasites: molecular genetics identifies Nramp1 as the Bcg/Ity/Lsh locus. J Leukoc Biol 58: 382-390.
130. Walker SL, Lockwood DN 2008. Leprosy type 1 (reversal) reactions and their management. Lepr Rev 79: 372-386.
131. Walker SL, Roberts CH, Atkinson SE, Khadge S, Macdonald M, Neupane KD, Ranjit C, Sapkota BR, Dhakal S, Hawksworth RA, Mahat K, Ruchal S, Hamal S, Hagge DA, Lockwood DN 2012. The effect of systemic corticosteroid therapy on the expression of Toll-like receptor 2 and Toll-like receptor 4 in the cutaneous lesions of leprosy type 1 reactions. Br J Dermatol 167: 29-35.
132. Walker SL, Waters MF, Lockwood DN 2007. The role of thalidomide in the management of erythema nodosum leprosum. Lepr Rev 78: 197-215.
133. Wang TT, Dabbas B, Laperriere D, Bitton AJ, Soualhine H, Tavera-Mendoza LE, Dionne S, Servant MJ, Bitton A, Seidman EG, Mader S, Behr MA, White JH 2010. Direct and indirect induction by 1,25-dihydroxyvitamin D3 of the NOD2/CARD15-defensin beta2 innate immune pathway defective in Crohn disease. J Biol Chem 285: 2227-2231.
134. Waters MF 2001. Distinguishing between relapse and late reversal reaction in multidrug (MDT)-treated BT leprosy. Lepr Rev 72: 250-253.
135. Wemambu SN, Turk JL, Waters MF, Rees RJ 1969. Erythema nodosum leprosum: a clinical manifestation of the arthus phenomenon. Lancet 2: 933-935.
136. White JH 2008. Vitamin D signaling, infectious diseases and regulation of innate immunity. Infect Immun 76: 3837-3843.
137. WHO - World Health Organization 2011. Leprosy update 2011. Wkly Epidemiol Rec 86: 389-399.
138. Wong SH, Gochhait S, Malhotra D, Pettersson FH, Teo YY, Khor CC, Rautanen A, Chapman SJ, Mills TC, Srivastava A, Rudko A, Freidin MB, Puzyrev VP, Ali S, Aggarwal S, Chopra R, Reddy BS, Garg VK, Roy S, Meisner S, Hazra SK, Saha B, Floyd S, Keating BJ, Kim C, Fairfax BP, Knight JC, Hill PC, Adegbola RA, Hakonarson H, Fine PE, Pitchappan RM, Bamezai RN, Hill AV, Vannberg FO 2010. Leprosy and the adaptation of human Toll-like receptor 1. PLoS Pathog 6: e1000979.
139. Wurfel MM, Gordon AC, Holden TD, Radella F, Strout J, Kajikawa O, Ruzinski JT, Rona G, Black RA, Stratton S, Jarvik GP, Hajjar AM, Nickerson DA, Rieder M, Sevransky J, Maloney JP, Moss M, Martin G, Shanholtz C, Garcia JG, Gao L, Brower R, Barnes KC, Walley KR, Russell JA, Martin TR 2008. Toll-like receptor 1 polymorphisms affect innate immune responses and outcomes in sepsis. Am J Respir Crit Care Med 178: 710-720.
140. Yang Han X, Clement Sizer K, Tan HH 2012. Identification of the leprosy agent Mycobacterium lepromatosis in Singapore. J Drugs Dermatol 11: 168-172.
141. Zhang FR, Huang W, Chen SM, Sun LD, Liu H, Li Y, Cui Y, Yan XX, Yang HT, Yang RD, Chu TS, Zhang C, Zhang L, Han JW, Yu GQ, Quan C, Yu YX, Zhang Z, Shi BQ, Zhang LH, Cheng H, Wang CY, Lin Y, Zheng HF, Fu XA, Zuo XB, Wang Q, Long H, Sun YP, Cheng YL, Tian HQ, Zhou FS, Liu HX, Lu WS, He SM, Du WL, Shen M, Jin QY, Wang Y, Low HQ, Erwin T, Yang NH, Li JY, Zhao X, Jiao YL, Mao LG, Yin G, Jiang ZX, Wang XD, Yu JP, Hu ZH, Gong CH, Liu YQ, Liu RY, Wang DM, Wei D, Liu JX, Cao WK, Cao HZ, Li YP, Yan WG, Wei SY, Wang KJ, Hibberd ML, Yang S, Zhang XJ, Liu JJ 2009. Genomewide association study of leprosy. N Engl J Med 361: 2609-2618.